PRMT5 and glioblastoma: A novel approach targeting protein arginine methyltransferase 5 (PRMT5), including a brain-penetrant PRMT5 inhibitor, has shown promise in preclinical studies wherein a specific splicing signature in GBM may predict responses to this drug class in vitro and in vivo (79).